Topics

MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy

19:00 EST 6 Nov 2019 | Cancer Networks

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.

Original Article: MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy

NEXT ARTICLE

More From BioPortfolio on "MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...